Under the terms of the agreement Nycomed will share brand responsibilities and expenses with Paladin and will deploy a national primary care sales force to promote Tridural. Paladin will continue to manage distribution of Tridural and will also continue to promote Tridural using its primary care sales force. The agreement will double the number of primary care sales representatives promoting Tridural in Canada.
James Howard-Tripp, president and CEO of Labopharm, said: “The addition of Nycomed’s sales force to that of Paladin will significantly expand the marketing and sales effort behind our product.”